Stakeholders’ knowledge, attitudes and practices to pharmacovigilance and adverse drug reaction reporting in clinical trials: a mixed methods study

被引:0
作者
David O. Riordan
Mary Kinane
Kieran A. Walsh
Frances Shiely
Joe Eustace
Margaret Bermingham
机构
[1] University College Cork (UCC),Health Research Board (HRB) Clinical Research Facility
[2] UCC,Pharmaceutical Care Research Group, School of Pharmacy
[3] UCC,HRB Clinical Research Facility and School of Public Health
来源
European Journal of Clinical Pharmacology | 2020年 / 76卷
关键词
Clinical trial; Pharmacovigilance; Adverse drug reaction reporting;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1363 / 1372
页数:9
相关论文
共 187 条
[1]  
Backstrom M(2007)Adverse drug reaction reporting by nurses in Sweden Eur J Clin Pharmacol 63 613-618
[2]  
Ekman E(2013)Gathering and exploring scientific knowledge in pharmacovigilance PLoS One 8 e83016-92
[3]  
Mjorndal T(2004)Differences between clinical trials and postmarketing use Br J Clin Pharmacol 57 86-437
[4]  
Lopes P(1999)Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain J Pain Symptom Manag 18 427-443
[5]  
Nunes T(2001)Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas JAMA 285 437-123
[6]  
Campos D(2007)What have we learnt from Vioxx? Bmj 334 120-570
[7]  
Furlong LI(2010)Rosiglitazone: what went wrong? Bmj 341 c4848-280
[8]  
Bauer-Mehren A(2011)Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations Clin Trials 8 559-101
[9]  
Sanz F(2016)Best practice for analysis of shared clinical trial data BMC Med Res Methodol 16 76-64
[10]  
Carrascosa MC(2001)Reporting of adverse drug reactions in randomised controlled trials-a systematic survey BMC Clin Pharmacol 1 3-1110